On Wednesday, Shares of PG&E Corporation (NYSE:PCG), subtract -4.21% and closed at $59.41 in the last trading session. The last trading range of the stock ranges between $59.34 and $60.85. PG&E Corporation (PCG) is a Fortune 200 energy-based holding company, headquartered in San Francisco. It is the parent company of Pacific Gas and Electric Company, an energy company that serves 16 million Californians across a 70,000 square-mile service area in Northern and Central California.
Nektar Therapeutics (NASDAQ:NKTR), jumped 4.06% and closed at $13.60 in the last trading session. The last trading range of the stock ranges between $13.10 and $14.16. The company’s Market capitalization is $2.12 Billion with the total Outstanding Shares of 152.84 million. Nektar Therapeutics (NKTR) recently declared that new Phase 1 clinical data for Nektar’s lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and Natural Killer (NK) cell abundance directly in the tumor micro-environment and increase expression of PD-1 on these immune cells. The results were presented by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in an oral presentation during recently’s session entitled “New Cancer Immunotherapy Agents in Development.”
Interim results presented were from the ongoing Phase 1 dose-escalation, first-in-human, trial of single-agent NKTR-214 in patients with locally advanced or metastatic solid tumors, counting melanoma, renal cell carcinoma (RCC), bladder, colorectal and other solid tumor cancers. A total of 20 patients were treated in four separate every three-week (q3w) dose cohorts (ranging from 0.003 mg/kg q3w to 0.012 mg/kg q3w) with 18 of these patients evaluable for anti-tumor activity. Based upon encouraging anti-tumor activity and tolerability of NKTR-214 observed at the 0.006 mg/kg q3w dose, an every two week (q2w) cohort of the 0.006 mg/kg dose began enrolling in September 2016 with an additional 5 patients enrolled to this cohort, all of which are continuing on therapy.